AI Article Synopsis

  • Aging causes an increase in somatic clones with cancer mutations in human tissues, but it's unclear if this occurs in the non-cancerous intestine.
  • Researchers analyzed whole-exome sequencing from 76 human colon organoids and discovered a specific pattern of mutations in patients with ulcerative colitis, particularly in genes related to IL-17 signaling.
  • These mutations help the epithelial cells resist cell death caused by IL-17A and may be associated with the worsening of colitis, suggesting that genetic changes in colon tissue can be linked to the underlying inflammation.

Article Abstract

With ageing, normal human tissues experience an expansion of somatic clones that carry cancer mutations. However, whether such clonal expansion exists in the non-neoplastic intestine remains unknown. Here, using whole-exome sequencing data from 76 clonal human colon organoids, we identify a unique pattern of somatic mutagenesis in the inflamed epithelium of patients with ulcerative colitis. The affected epithelium accumulates somatic mutations in multiple genes that are related to IL-17 signalling-including NFKBIZ, ZC3H12A and PIGR, which are genes that are rarely affected in colon cancer. Targeted sequencing validates the pervasive spread of mutations that are related to IL-17 signalling. Unbiased CRISPR-based knockout screening in colon organoids reveals that the mutations confer resistance to the pro-apoptotic response that is induced by IL-17A. Some of these genetic mutations are known to exacerbate experimental colitis in mice, and somatic mutagenesis in human colon epithelium may be causally linked to the inflammatory process. Our findings highlight a genetic landscape that adapts to a hostile microenvironment, and demonstrate its potential contribution to the pathogenesis of ulcerative colitis.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41586-019-1844-5DOI Listing

Publication Analysis

Top Keywords

ulcerative colitis
12
colitis epithelium
8
human colon
8
colon organoids
8
somatic mutagenesis
8
mutations
6
somatic
5
somatic inflammatory
4
inflammatory gene
4
gene mutations
4

Similar Publications

Background/objectives: Ulcerative colitis (UC) is a chronic and easily recurrent inflammatory bowel disease. The gut microbiota and plasma metabolites play pivotal roles in the development and progression of UC. Therefore, therapeutic strategies targeting the intestinal flora or plasma metabolites offer promising avenues for the treatment of UC.

View Article and Find Full Text PDF

Background/objectives: Janus kinase inhibitors open new horizons for small-molecule drugs in treating inflammatory bowel disease, with ritlecitinib demonstrating significant efficacy in clinical trials for ulcerative colitis and Crohn's disease. Ritlecitinib, a second-generation JAK3 inhibitor, is a novel therapeutic agent for alopecia areata and other autoimmune conditions.

Methods: A new stability-indicating UHPLC-DAD-MS/MS method was developed, validated, and applied for a forced degradation study of ritlecitinib under ICH guidelines.

View Article and Find Full Text PDF

Quinazolinone Derivative MR2938 Protects DSS-Induced Barrier Dysfunction in Mice Through Regulating Gut Microbiota.

Pharmaceuticals (Basel)

January 2025

MOE Key Laboratory of Marine Drugs, MOE Key Laboratory of Evolution & Marine Biodiversity, School of Medicine and Pharmacy, Institute of Evolution & Marine Biodiversity, College of Food Science and Engineering, Ocean University of China, Qingdao 266003, China.

: Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), is characterized by colorectal immune infiltration and significant microbiota compositional changes. Gut microbiota homeostasis is necessary to maintain the healthy state of humans. MR2938, a quinazolin-4(3H)-one derivative derived from the marine natural product penipanoid C, alleviated DSS-induced colitis in a dose-dependent manner.

View Article and Find Full Text PDF

Inflammatory bowel diseases (IBD) including Crohn's disease (CD) and ulcerative colitis (UC) are chronic, relapsing conditions characterized by dysregulated immune responses and persistent intestinal inflammation. This review aims to examine new potential therapeutic targets in IBD starting from the STRIDE-II statements. Key targets now include clinical remission, endoscopic remission, and biomarker normalization (such as C-reactive protein and fecal calprotectin).

View Article and Find Full Text PDF

Background: (-)-Fenchone is a bicyclic monoterpene present in the plant species Mill, L. (tuja), and (lavender). These plants have therapeutic value in the treatment of intestinal disorders.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!